Introduction
Cellularm olecular responses to focal tissue hypoxia are critical to the development and prognosis of severalc linical pathologies, including cancer, [1] liver disease, [2] myocardial and peripheral vascular diseases, [3] diabetes [4] and arthritis. [5] In cancer, electron-affinic, bioreductivelya ctivated oxygen-mimetics, particularlyt he 2-nitroimidazoles (2-NI;a zomycin) have been investigated as radiosensitizer adjuncts for X-ray radiotherapy of radioresistant hypoxicc ells [6] [7] [8] and as imaging diagnostics of hypoxict umor. [9] [10] [11] [12] [13] [14] In general, these radiosensitizers have failed to perform effectively as neo-adjuvants to radiation therapy.I nt he case of nitroimidazoles, the narrow therapeutic window and related dose-limiting toxicities have contributed to their clinical ineffectiveness. [15] For imaging focal hypoxia, however,t he nitroimidazole-basedr adiotracers have been effective. Several PET tracers,i ncluding fluorine-18-fluoromisonidazole ([ 18 F]FMISO) [16] and fluorine-18-fluoroazomycin arabinoIodoglucoazomycin( I-GAZ; N-(2-iodo-3-(6-O-glucosyl)propyl)-2-nitroimidazole), an on-glycosidic nitroimidazole-6-O-glucose adduct, was synthesized,r adioiodinated, and evaluated as as ubstrate of glucose transporter1(GLUT1) for radiotheranostic (therapy + diagnostic) management of hypoxic tumors. Nucleophilic iodination of the nosylate synthon of I-GAZ followed by deprotectiona fforded I-GAZ in 74 %o verall yield. I-GAZ was radioiodinatedv ia 'exchange' labeling using [ 123/131 I]iodide (50-70 %R CY)a nd then purified by Sep-Pak (> 96 %R CP). [
131 I]I-GAZ was stable in 2% ethanolics olutioni ns terile water for 14 days when stored at 5 8C. In cell culture, I-GAZ was found to be nontoxic to EMT-6 cells at concentrations < 0.5 mm,a nd weaklyr adiosensitizing (SER 1.1a t1 0% survival of EMT-6 cells;
1.2 at 0.1 %s urvival in MCF-7 cells). The hypoxic/normoxic uptake ratio of [
123 I]I-GAZ in EMT-6 cells was 1.46 at 2h,a nd under normoxic conditions the uptake of [
123 I]I-GAZ by EMT-6 cells was unaltered in the presence of 5mm glucose. The biodistribution of [
131 I]I-GAZ in EMT-6 tumor-bearing Balb/c mice demonstrated rapid clearance from blood and extensive renal and hepatice xcretion.T umor/blood and tumor/muscle ratios reached~3a nd 8, respectively,a t4hp ost-injection.R egression analysis of the first order polynomial plots of the blood and tumor radioactivity concentrationss upported ap erfusionexcretion model with low hypoxia-dependent binding. [
131 I]I-GAZ was found to be stable in vivo, and did not deiodinate. [17, 18] and the SPECT agenti odine-123-iodoazomycin arabinoside ([ 123 I]IAZA) [19] have found extensive clinical use in hypoxia detection in canceri maging (Figure 1 ). Althought hese agents have performed well enough to justify their continued use in patient studies, all, withoute xception, achieve relativelyl ow target-background concentration ratios and hence lead to low-contrast images. [12] Their performance as imaging agents reflects their diffusion-based local delivery to hypoxic cells (i.e.,p harmacokinetics) and to al esser extent, their oxygen-dependent bindingr ates (i.e.,e lectron affinity). [7, [20] [21] [22] [23] [24] Their poor performance as in vivo radiosensitizers when used in conjunction with X-ray treatmenth as been attributed to their inability to achieve radiosensitizing concentrations at dose-limitingn eurotoxicities. [25] The consensus remains that there is still ac linicaln eed for more effectiver adiosensitizers. [26] Approachest oo btaining more rapid, hypoxia-sensitive uptake of electron-affinic nitroimidazole derivatives by hypoxic cells have focused on exploitation of equilibrative and concentrative transmembrane transport proteins, including nucleoside transporters, [23] amino-acid transporters [27] andg lucose transporters (GLUTs). [28] [29] [30] For example, the design of selected glucose-C6-O-azomycina dducts [29, 30] wasr ationalized from the reported GLUT1 transport of the corresponding C6-O-glucose-NBD adduct, 6-NBDG. [31] GLUTsa re particularlya ttractive transport elements to support imaging and/or molecular radiotherapy (MRT) of hypoxia because several GLUT subtypes, includingG LUT1,a re upregulated in hypoxic cells. [32] Thep arentc ompound of the glucose-C6-O-azomycina dduct series, N-(2-hydroxy-3-(6-O-glucosyl)-propyl)-2-nitroimidazole (GAZ), was found to be nontoxic but only weakly radiosensitizing to hypoxic cells in cell culture. [29] The fluoro analogue, F-GAZ (N-(2-fluoro-3-(6-O-glucosyl)propyl)-2-nitroimidazole; fluoroglucoazomycin), was weakly competitivea gainst [ 18 F]FDG uptake in cell culture, and therefore considered to accumulate independently of transport via GLUT1.H owever in PET imaging studies, [ 18 F]F-GAZ did delineate hypoxic tumor in am urine model. [30] EMT-6 tumors, despite rapid renal clearance kinetics of [ 18 F]F-GAZ, exhibited prolonged retention of low levels radioactivity (~1%ID/g at 60 min) after injection of carrier-added (100 mg kg À1 )d oses. This indicates that these compounds have potential for use as adjunctt herapeutics (i.e.,a sr adiosensitizers) for externalb eam radiotherapy (XRT), or as molecularr adiotherapeutics( MRT) to supplementX RT if radiotherapeutic radionuclides were used in place of fluorine-18. [30] The current work describes the synthesis, radiolabeling chemistry,i nvitro biology and in vivo biodistribution of I-GAZ (N-(2-iodo-3-(6-O-glucosyl)propyl)-2-nitroimidazole;i odoglucoazomycin). I-GAZ is more lipophilic than GAZ and F-GAZ and was therefore expected to displaya lteredp harmacokinetics that could lead to improved uptake in target tissues.
Results and Discussion

Chemistry and radiolabeling
As depicted in Scheme 1, synthesis of the target compound, I-GAZ, was achieved starting from the advanced intermediate, 1, which was previously synthesized in our laboratory. [29] Treatment of nosylate 1 with sodium iodide in DMF followed by in situ acetolysis of the resulting product using 0.1 m methanolic sodium methoxide afforded I-GAZ in 74 %y ield over two steps.T he structure of the target compound was confirmed using 1 HNMR, 13 CNMR spectroscopies and high-resolution mass spectrometry (HRMS).
Radioiodine exchange radiolabeling of cold I-GAZ was selected as the preferred labeling method. An umber of preliminary reactions with various solvents [acetonitrile, 1,2-dimethoxyethane (DME), dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF),m ethyl ethyl ketone (MEK)],w ith and without pivalic acid (data not shown) led to the selection of exchange radioiodination using pivalic acid melt conditions, [33] followed by recovery and purification by Sep-Pak filtration, to afford the labeled radiopharmaceuticali nr adiochemical yields (RCY) of 50-70 %a nd radiochemicalp uritieso f9 6-99 %. The purification of [ 
In vitro evaluations of I-GAZ
Previous investigations of this class of halo-glucose-nitroimidazole adducts showed that these compounds werew eakly cyto- www.chemmedchem.org toxic, with inhibitory concentrations( IC 50 )i nt he 0.5 mm range and with low uptake under cell culture conditions. [29, 30] I-GAZ toxicityw as similarly apparent at concentrations of 0.5 mm and greater,asshown ( Figure 3 ). This was in line with the longstanding concept that nitroimidazoles have ap referential toxicity towardh ypoxic rather than normoxic cells, and that this toxicitya rises through the formation of several bioreducedi ntermediates of thenitro moiety. [34] [35] [36] [37] [38] In vitro radiosensitization
In vitro radiosensitizer potency mayb ee xpressed as the sensitizer enhancement ratio (SER). In vitro SERs are often determined at relatively high concentrations (i.e.,1m m), [39] but the toxicityo ft he putative radiosensitizerm ust be considered when conducting these experiments. For I-GAZ,i tw as determined that ac oncentration of 0.5 mm could be used with minimal cytotoxicity.T he radiosensitization (SER~1.1) induced by I-GAZ at this concentration would appear to preclude effective in vivo radiosensitization. In the currentw ork, normoxic/hypoxic SER data for EMT-6 cells could only be measured at the 10 % cell survival levels, which would be too high form eaningful interpretation or application using in vivo models. Lower surviving fractions, say < 1%,w ould have required high radiation doses that the radiation source available for this work could not deliver within ar easonable time frame.N onetheless, the oxygen enhancement ratio (OER) measured at the 10 %survival dose was~3, therebyv alidating the experiment procedure ( Figure 4 ).
Data for MCF-7 cells indicated an OER of~2.3, and aS ER of 1.2 at an I-GAZ concentration of 0.5 mm (Table 1) . Ta rget SERs of 1.5-1.8 have been reported for several 2-nitroimidazoles in cell culture, for radiosensitizerc oncentrations of 1.6 mm. [7] . Data are plotted as percentages of the normalized surviving fraction;error bars depict 1standard deviation (n = 4f or controls, i.e.,n or adiation; n = 3f or irradiated cultures).V ertical drop-lines point to radiation doses (Gy) for the respective survival level (10 and 1% for EMT-6 and MCF-7, respectively) for each treatment (air,n itrogen, nitrogen with I-GAZ)were used to calculateOER and SERfor each cell line. Clearly,d etermination of the radiosensitization properties and sensitization efficiency of I-GAZ in vitro andi nvivo, including measurement of its in vivo intratumor concentrations would be required.
In vitro I-GAZ-GLUT interaction
The glucose-nitroimidazole adduct family of radiosensitizers was initially designed to be transported into cells by GLUT proteins. [28] Studies of F-GAZ competition with [ 18 F]FDG indicated that F-GAZ is aw eak competitor for transport, especially in the presenceo fp hysiological concentrations of glucose in cell culture. [29] In the current work, [
123 I]I-GAZ and [ 18 F]FDG were incubated in vitro in EMT-6 cell culture to provide further clarification of the I-GAZ-GLUT interaction, this time using glucose at either physiological or decreased (nominally zero, as no glucose was included in the culture mediumd uringt he experiments) concentrationsast he competitive substrate ( Figure 5 ).
Biodistribution of radioactivity (BR)
BR in tissues of Balb/c mice bearing implanted EMT-6 tumors was determined periodically over 24 hf ollowingabolus intra-
In general, the data depict low penetration intos oft tissues (muscle, adipose tissue, pancreas and spleen), and rapid entry into the hepatobiliary (liver,g all bladder and intestines) and renal (kidney) excretory organs. Radioactivity levels in stomach and thyroid remained low throughout the study period.T umor radioactivity was intermediate between non-excretory and excretory tissues. In terms of total uptake andc learance over time, these data support am odel of low extravascular distribution, rapid renal clearance attributable to the high hydrophilicity of I-GAZ, and extensive hepatobiliary clearance commensurate with its high molecular weight. Fluctuations in gall bladder radioactivity and persistent small intestiner adioactivity may be an indication of enterohepatic recycling of [
131 I]I-GAZa nd/or metabolites (see the SupportingI nformation for detailed data).
Comparisonso fc oncentrations in tumor/blood and tumor/ muscle are indicative of hypoxia-specific uptake and retention of radioactivity in hypoxict umor,a nd in turn, the possibility of using www.chemmedchem.org ence of hypoxicc ells) than the standardized absolute uptake of the tracer (e.g.,s tandard uptake value, SUV max ). [39] In the case of [
131 I]I-GAZ evaluation in mice, concentrations of radiotracer in EMT-6 tumor were 2-3 times higher than blood radioactivity in the 1-4 hw indow after injection, representing about one percent of the injected dose. However,r egression analysiso ft he first-order polynomial plots of the blood and tumor radioactivityc oncentrations indicated that the clearance of [
131 I]I-GAZ from both tissues followed as imilart ime course (Figure 8) 
Conclusions
The synthesis of unlabeled and radioiodinatedI -GAZ, which were readily obtained through iodination and then deprotection of the versatile synthon
1-a/b-d-(1,2,3,4-tetra-O-acetyl)-6-O-(9-[2-nitro-1H-imidazolyl]-8R/S-O-(4-nitrobenzenesulfonyloxy)propyl)glucopyranose (acetylglucoazomycin nosylate;
A c-GAZ-Ns) are reported. The radiolabeled product,[ 131 I]I-GAZ, was stable for at least 14 days when kept in 2% ethanol in sterile water at 22 8C.
In vitro studies showedt hat I-GAZ is ar elatively weak radiosensitizer when tested at its in vitro IC 50 concentration (0.5 mm), especially against EMT-6 cells (SER 1.1 at 10 %s urvival). The SER for MCF-7 cells was~1.2 at 1% survival. In cell culture (EMT-6 cells),[ 131 I]I-GAZ uptake was almost 50 %h igher under hypoxiat han under air,d emonstrating hypoxia-dependent binding,b ut cellular uptake of [ 131 I]I-GAZ was virtuallyi ndependento ft he presence or absence of glucose,i ndicating that transport by GLUT was not an important factor in its uptake. In summary,t he in vitro data provide evidenceo fI - www.chemmedchem.org GAZ bioreduction leadingt oh ighert oxicity and increased retention in hypoxic cells, as would be expected for 2-nitroimidazoles. However,I -GAZ was only aw eak radiosensitizer of EMT-6 and MCF-7 cells under the prescribed experimental conditions. The independence of cell uptake on the presence or absence of glucosei nt he culture mediumwas taken as evidence that I-GAZ uptake is not GLUT-mediated.
In vivo biodistribution studies of [ 131 I]I-GAZ in Balb/c mice with implanted EMT-6 tumors provided evidence for rapid clearance from blood, extensive renal butp redominantly hepatic excretion, and stability against deiodination.T umor/blood ratios exceeded unity within 30 min, and rose to~3a t4h, whereas tumor/muscle ratios rose from~3o ver the first h, tõ 8a t4hp ost-injection. Analysis of temporal blood and tumor radioactivity after injection revealed quantitative similarities between the two sets of data (Figure 8 ).
Experimental Section
General synthesis methods:S olvents used in reactions were purified before use by successive passage through columns of alumina and copper under an argon atmosphere. All reagents were purchased from commercial sources, and were used without further purification unless noted otherwise. All reactions were carried out under ap ositive pressure argon atmosphere and monitored by TLC on Silica Gel G-25 UV 254 (0.25 mm) unless stated otherwise. TLC spots were detected under UV light and/or by charring with asolution of anisaldehyde in EtOH, acetic acid and H 2 SO 4 .C olumn chromatography was performed on Silica Gel 60 (40-60 mm). The ratio between silica gel and crude product ranged from 100:1 to 20:1 (w/w). Organic solutions were concentrated under vacuum at < 50 8C. HC OSY and HMQC) experiments. ESI-MS spectra were obtained on samples suspended in CH 3 OH with added NaCl. Atomic numbering for I-GAZ is shown in Figure 9 .
anose, I-GAZ:N aI (21.18 mg, 0.14 mmol) was added to as olution of compound 1 [29] (50 mg, 0.07 mmol) in DMF (3 mL), and the reaction mixture was heated at 60 8Cf or 3h.T he reaction was quenched with H 2 O( 10 mL) and the product was extracted into EtOAc (10 mL). The organic layer was dried using Na 2 SO 4 ,f iltered, and the solvent was removed under reduced pressure. To asolution of the crude product in CH 2 Cl 2 (3 mL), 0.1 m methanolic NaOCH 3 (3 mL) was added and the solution stirred at 22 8Cf or 20 min. The reaction mixture was neutralized with Amberlite IR-120 H + resin, filtered, and the solvent was removed. The impure product was purified by column chromatography ( I) exchange under pivalic acid melt conditions (Scheme 1). In at ypical reaction, solutions of I-GAZ (100 mg) in EtOH (50 mL) and pivalic acid (1 mg in 50 mLE tOH) were added to ap re-warmed V-vial (heating block;4 08C) containing Na[
131 I]I (185 MBq) in methanolic NaOH (100 mLC H 3 OH and 2 mLa queous 0.05 n NaOH). The solvent was evaporated under ag entle stream of argon gas to bring the melt to dryness (~27 min). An additional portion of dry EtOH (100 mL) was added to the vial, and the solvent was again removed under argon. Complete removal of residual traces of water in the reaction mixture was achieved using ah igh vacuum pump. Anhydrous acetonitrile (CH 3 CN;1 00 mL) was added to the vial, which was then capped and placed on the pre-heated block heater (100 8C). The reaction was allowed to proceed at this temperature for 2h,a fter which the vial was removed from the block heater and cooled to 30 8C. The solvent was removed under af low of argon, the residue was dissolved in sterile water for injection (SWFI;2 00 mL2), and withdrawn into as yringe. AC 18 Sep-Pak cartridge, preconditioned by flushing with EtOH (2 mL) followed by SWFI (10 mL), and then air-dried by flushing with air (10 mL), was attached to this syringe and the reaction mixture was pushed slowly onto the cartridge;t he wash was collected in av ial (iodide vial). The syringe was removed and the cartridge was flushed with SWFI (4 mL) to remove unreacted sodium [ 131 I]iodide, which was also collected in the 'iodide vial' (total 56 MBq). Finally,t he cartridge was eluted with 5% EtOH in SWFI (2 mL) to afford the pure radiopharmaceutical, which was collected in ac lean pre-evacuated sterile vial. At ypical reaction afforded 100 MBq of radiodinated I-GAZ (recovered radiochemical yield;rRCY;54%)with aradiochemical purity (RCP) > 96 %b yT LC. TLC radiochromatograms of the 'iodide' and 'product' solutions are shown in Figure 1. [ 123 I]IAZA was prepared by radioiodide exchange with IAZA using al iterature technique. [33] Cytotoxicity:E xponentially-growing murine EMT-6 and human MCF-7 cell cultures (American Type Culture Collection;A TCC;U SA) were trypsinized, collected and diluted in the appropriate medium to ac ell concentration of 810 3 cells per mL. Cells (8 10 2 cells in 100 mL) were seeded into 96-well plates and incubated (24 h; 37 8C) under either 5% CO 2 in air,o ru nder nitrogen. I-GAZ was dissolved at the desired concentrations in growth medium, and the resulting I-GAZ solutions (100 mL) were added to the cell-containing wells. Hypoxic conditions under nitrogen were created by suc- Figure 9 . The structureofI -GAZ and atom assignments used for chemical and spectral data. ChemMedChem 2016 ChemMedChem , 11,1638 ChemMedChem -1645 www.chemmedchem.org cessive evacuation/refill cycles with high purity nitrogen. In controls (hypoxic and aerobic), medium (100 mL) replaced the testcompound solution. After a7 2hincubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT,5 0mLo f1mg mL À1 solution) was added to each well, and after a4hi ncubation the supernatant was removed and DMSO (150 mL) was added to each well to dissolve the formazan crystals. The well-plates were shaken for 30 min to ensure complete extraction, then scanned at 540 nm using an ELISA reader.S urvival curves ( Figure 2) were generated from net (test minus control) optical density data.
Radiosensitization:H uman MCF-7 and murine EMT-6 cells (300 000 cells in 3mLD MEM/F12 medium per T60 glass Petri dish) were incubated (37 8C, 20 h) under 5% CO 2 in air.I -GAZ (stock solution 10 mm in 95 %E tOH) was then added to achieve ac oncentration of 100 mm,a nd incubation was continued for 24 h. Dishes were assigned to either the control (normoxic) or hypoxic groups. Those in the hypoxic group were de-gassed to hypoxia by six consecutive vacuum/nitrogen (high purity) fill cycles in av acuum chamber.T he Petri dishes (hypoxic and normoxic controls) were then incubated for 30 min on an oscillating shaker at 37 8C( 60 cycles/min) and irradiated in a68Co g-irradiator to 0( control), 4, 8, 16 and 32 Gy in either N 2 (hypoxic sub-group) or air (normoxic sub-group up to 8Gy) chambers. The cells were sequentially washed with PBS, trypsinized (500 mL), quenched with fresh medium (4.5 mL), plated in medium at densities ranging from 100 to 15 000 cells per 5mL medium (normoxic cells;1 00 and 5000 cells per 5mLm edium for hypoxic cells), and then incubated (37 8C; 5% CO 2 in air). After 10 to 14 days, cells were stained with methylene blue or crystal violet in EtOH, then clones were counted and surviving fractions calculated. Data are shown in Figure 3 .
Hypoxia dependent uptake in vitro:I naseparate experiment, [ 131 I]I-GAZ or [
131 I]IAZA were incubated with EMT-6 cells (10 6 mL) in culture medium under either air (with 5% CO 2 )o rn itrogen (hypoxic conditions were created by successive evacuation/refill cycles with high purity nitrogen). After 2h,t he cell incubates were treated with trichloroacetic acid (TCA) and the precipitate (bound tracer) was recovered on af iber filter bed, washed with cold water (2 1 mL) and radioassayed using a g-counter.R adioactivity uptake data (cpm per well) was transposed for expression as pmol per 10 6 cells.
In vitro cell uptake of [ 123 I]I-GAZ:E MT-6 cells (obtained from Dr. David Murray,C ross Cancer Institute, University of Alberta) were cultured at 37 8Ci nahumidified atmosphere of 5% (v/v)C O 2 , using DMEM/F12 medium supplemented with 10 %f etal bovine serum (FBS), 2mml -glutamine and 1% antibiotic/antimycotic (Invitrogen, Burlington, ON, Canada). Cell growth medium was changed every second day and cells were tested against mycoplasma contamination. Exponentially growing cells were sub-cultured into 12-well plates (Corning, Lowell, MA, USA) 24 hb efore the radiotracer uptake experiment at ad ensity that gave rise to > 85 % confluence on the experimental day.B efore the experiment, the growth medium was removed and the cells were washed once with Krebs-Ringer buffer (120 mm NaCl, 25 mm NaHCO 3 ,4m m KCl, 1.2 mm KH 2 PO4, 2.5 mm MgSO 4 ,7 0 mm CaCl 2 ,p H7.4). The cells were subsequently incubated in Krebs-Ringer buffer for 1hbefore radiotracer incubation was started. The radiotracer [
123 I]I-GAZ was diluted in either Krebs-Ringer buffer with or without addition of 5mm glucose to~500 kBq per mL buffer solution. Cells were incubated with [
123 I]I-GAZ containing buffer solution at 37 8Cf or 1min up to 90 min. Radiotracer uptake was stopped at dedicated time points by washing the cells with ice-cold Krebs-Ringer buffer twice. Cells were lysed with 5% (TCA) at 37 8Cf or 5min and transferred into scintillation vials. The cell lysate was counted in a gcounter (Wallac 1480 Wizard-3, PerkinElmer,C anada). Protein levels were quantified using the BCA protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturer'sr ecommendations;b ovine serum albumin was used as the protein standard. Cell uptake levels were normalized to percent of the total added amount of radioactivity corresponding to exposure dose (% ED) per mg protein (Figure 4) .
Biodistribution of [
131 I]I-GAZ in subcutaneous EMT-6 tumors bearing Balb/c mice:T he animal experiments were carried out in accordance with guidelines of the Canadian Council on Animal Care (CCAC), and were approved by the local animal care committee of the Cross Cancer Institute. Murine EMT-6 cells (5 10 6 cells in 100 mLP BS) were injected into the upper left flank of female Balb/ cm ice (20-24 g, Charles River,C anada). The biodistribution experiment was performed after allowing 8t o1 1d ays for the tumors to grow.T he EMT-6 tumors analyzed in this study reached final sizes of 171.5 AE 9.8 mg (n = 15). After intravenous (i.v.) injection of [
131 I]I-GAZ (170-190 kBq in 100 mLs aline) into the tail vein of isoflurane anesthetized mice, the animals were allowed to regain consciousness until sacrifice. Animals were euthanized in aC O 2 chamber at 5, 30, 60 min and at 4and 24 hpost-injection, and then rapidly dissected. Organs of interest (blood, heart, lung, liver,k idneys, gall bladder,s pleen, stomach, duodenum, small and large intestines, pancreas, right femur,m uscle, ovaries, brain, fat, thyroid and tumors) were collected and weighed. Radioactivity in all tissue samples was measured in a g-counter and results were analyzed as percentage of injected dose per gram (%ID/g) of tissue (Table 1) .
